RSV/Synagis Season
RSV 2025/2026 season
Beyfortus (nirsevimab) and Enflonsia (clesrovimab) are the first-line recommended immunization products for administration to infants to protect against medically attended RSV disease.
A total of five (5) doses between December 1, 2025 - April 30, 2026, will be allowed for the 2025/2026 Synagis season.
For questions, please call 1-877-644-4613.